PHOSLURE 400MG TABLET

Description / Action:

Phoslure tablets contain sevelamer carbonate which is a calcium-free, aluminium-free, non-metal phosphate binder for dogs & cats. It supports kidney health in dogs and cats suffering from hyperphosphatemia.

Chronic kidney disease (CKD) is a common, irreversible, and progressive disease in dogs and cats.

In patients with CKD, mineral and bone disorders occur due to impaired kidney function.

Hyperphosphatemia is known to be a prognostic factor for shorter survival time in dogs with CKD.

Therefore, prevention and management of hyperphosphatemia may improve the prognosis of dogs and cats with CKD.

Shortcomings With Current Phosphate Binders:

Calcium-based phosphate binders

Risk of hypercalcemia
Increased risk for soft tissue and vascular calcification, and may also be a risk factor for calciphylaxis.
Restriction of total intake of calcium prevents the use of calcium-containing binders at doses sufficient to adequately control serum phosphate.

Lanthanum carbonate

Concern of accumulation of lanthanum in bone, liver, and gastric mucosa reported

Aluminium containing phosphate binders

Risk of aluminium toxicity; reported in dogs with renal disease after 2 to 6 weeks on doses of 126 to 200 mg/kg/day of aluminium hydroxide
Signs of toxicity includes lethargy, neurologic signs, progressive microcytosis microcytic anaemia
Evaluation of red blood cell (RBC) in all animals receiving aluminium-containing phosphate binders is suggested

Chitosan based phosphate binders

Persistent low levels of serum phosphorus even after discontinuation of therapy attributed to a residual effect of chitosan bound to the intestinal tract because of its muco-adhesive properties
Reduction in PTH levels

Class: Phosphate Binder

Indication / Uses:


Sevelamer is indicated in dogs and cats for

Treats hyperphosphatemia in patients with chronic kidney disease without the risk of hypercalcemia or aluminium toxicity
Significantly slows the progression of vascular calcification as compared to calcium phosphate binders
Reduces cardiovascular morbidity and mortality.

Dosage and administration:

Cats & Small Dogs 1/2 tablet 2-3 times daily with meals

Medium & Large dogs 1 tablet daily with meals

Ref: Plumb’s Veterinary Drug Handbook 6th ed.

Direction for use:

Dissolve one tablet in 5-10ml of water. Draw the solution in a suitable syringe and administer directly in mouth of the pet

Phoslure Tablets
Sevelamer carbonate 400mg Dispersible Tablets
Calcium-free, aluminium-free, non-metal phosphate binder for dogs & cats

Manufactured by: SAVA VET / SAVA Healthcare Limited

Doses form: Tablets

Presentation:

10 X 10 Tablets Box

Ingredients & Composition:

Each uncoated dispersible tablet contains
Sevelamer carbonate 400mg
Excipients q.s.

Description / Action:

Phoslure tablets contain sevelamer carbonate which is a calcium-free, aluminium-free, non-metal phosphate binder for dogs & cats. It supports kidney health in dogs and cats suffering from hyperphosphatemia.

Chronic kidney disease (CKD) is a common, irreversible, and progressive disease in dogs and cats.

In patients with CKD, mineral and bone disorders occur due to impaired kidney function.

Hyperphosphatemia is known to be a prognostic factor for shorter survival time in dogs with CKD.

Therefore, prevention and management of hyperphosphatemia may improve the prognosis of dogs and cats with CKD.

Shortcomings With Current Phosphate Binders:

Calcium-based phosphate binders

Risk of hypercalcemia
Increased risk for soft tissue and vascular calcification, and may also be a risk factor for calciphylaxis.
Restriction of total intake of calcium prevents the use of calcium-containing binders at doses sufficient to adequately control serum phosphate.

Lanthanum carbonate

Concern of accumulation of lanthanum in bone, liver, and gastric mucosa reported

Aluminium containing phosphate binders

Risk of aluminium toxicity; reported in dogs with renal disease after 2 to 6 weeks on doses of 126 to 200 mg/kg/day of aluminium hydroxide
Signs of toxicity includes lethargy, neurologic signs, progressive microcytosis microcytic anaemia
Evaluation of red blood cell (RBC) in all animals receiving aluminium-containing phosphate binders is suggested

Chitosan based phosphate binders

Persistent low levels of serum phosphorus even after discontinuation of therapy attributed to a residual effect of chitosan bound to the intestinal tract because of its muco-adhesive properties
Reduction in PTH levels

Class: Phosphate Binder

Indication / Uses:


Sevelamer is indicated in dogs and cats for

Treats hyperphosphatemia in patients with chronic kidney disease without the risk of hypercalcemia or aluminium toxicity
Significantly slows the progression of vascular calcification as compared to calcium phosphate binders
Reduces cardiovascular morbidity and mortality.

Dosage and administration:

Cats & Small Dogs 1/2 tablet 2-3 times daily with meals

Medium & Large dogs 1 tablet daily with meals

Ref: Plumb’s Veterinary Drug Handbook 6th ed.

Direction for use:

Dissolve one tablet in 5-10ml of water. Draw the solution in a suitable syringe and administer directly in mouth of the pet